中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.016 seconds)

    Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization
    13.
    发明申请
    Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization 有权

    公开(公告)号：US20240368235A1

    公开(公告)日：2024-11-07

    申请号：US18776908

    申请日：2024-07-18

    Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

    Inventor： Katsuto TAMAI ,  Takashi SHIMBO ,  Takehiko YAMAZAKI

    IPC: C07K14/47 ,  A61K38/00 ,  A61P1/00 ,  A61P17/06 ,  A61P37/06

    Abstract: The present inventors identified many nuclear proteins contained in the extract of skin tissue by mass spectrometry, randomly selected multiple partial amino acid sequences of the nuclear proteins, chemically synthesized peptides consisting of the partial amino acid sequences, and examined their activity of mobilizing mesenchymal stem cells. As a result, it was found that these multiple peptides show the activity of mobilizing mesenchymal stem cells into peripheral blood, even though their amino acid sequences are completely different from each other. The inventors also found that fragment peptides of the nuclear proteins have therapeutic effects on diseases characterized by inflammation and abnormalities of the immune system (e.g., inflammatory bowel disease and psoriasis). Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.

    Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
    15.
    发明授权
    Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure 有权

    公开(公告)号：US11826401B2

    公开(公告)日：2023-11-28

    申请号：US16477878

    申请日：2018-01-26

    Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

    Inventor： Katsuto Tamai ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Takashi Kido ,  Takasumi Goto ,  Takehiko Yamazaki

    IPC: A61K38/00 ,  C07K14/00 ,  A61K38/19 ,  A61P9/10

    CPC classification number: A61K38/19 ,  A61P9/10

    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.

    FORMULATION CONTAINING HMGB1 PARTIAL PEPTIDE
    17.
    发明公开
    FORMULATION CONTAINING HMGB1 PARTIAL PEPTIDE 审中-公开

    公开(公告)号：US20230173027A1

    公开(公告)日：2023-06-08

    申请号：US17919872

    申请日：2021-04-19

    Applicant: Shionogi & Co., Ltd. ,  StemRim Inc.

    Inventor： Nao MATSUOKA ,  Shuichi HATANO ,  Yuya KUGA ,  Maki OKABE ,  Takehiko YAMAZAKI ,  Koichi YOKOTA

    IPC: A61K38/19 ,  A61K47/12 ,  A61K47/26 ,  A61K47/02 ,  A61K9/19

    CPC classification number: A61K38/19 ,  A61K47/12 ,  A61K47/26 ,  A61K47/02 ,  A61K9/19

    Abstract: A pharmaceutical composition containing the substance according to any one of the following (a) to (c), an organic acid, a metal salt of an organic acid, and a sugar and/or a sugar alcohol, wherein when the pharmaceutical composition is dissolved in distilled water for injection, a pH of the pharmaceutical composition is 3.0 to 4.5, the substance according to any one of the following (a) to (c) can be stabilized;



    (a) an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or an acid addition salt thereof;
    (b) a peptide comprising an amino acid sequence having substitution, deletion, insertion or addition of one or more amino acids in the amino acid sequence set forth in SEQ ID NO: 1, and having an activity of stimulating migration of a cell, or an acid addition salt thereof; and
    (c) a peptide comprising an amino acid sequence having about 80% or more of sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, and having an activity of stimulating migration of a cell, or an acid addition salt thereof.

    Therapeutic Agent for Psoriasis
    18.
    发明申请
    Therapeutic Agent for Psoriasis 有权

    公开(公告)号：US20220380420A1

    公开(公告)日：2022-12-01

    申请号：US17817084

    申请日：2022-08-03

    Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

    Inventor： Katsuto TAMAI ,  Takashi SHIMBO ,  Takehiko YAMAZAKI

    IPC: C07K14/47 ,  A61P17/06

    Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.

Patent Agency Ranking